Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Lymphomas are blood cancer which occur when the white blood cells grow abnormally. Lymphomas are categorized into three main types: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Hodgkin Lymphoma (Hodgkin's disease), and Non-Hodgkin Lymphoma (NHL). The Hodgkin Lymphoma (Hodgkin's disease) involves Reed-Sternberg cells and is less prevalent while the lymphomas which do not involve Reed-Sternberg cells are categorized under Non-Hodgkin Lymphoma (NHL) and are more prevalent then Hodgkin Lymphomas.

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) which affects the B-lymphocytes and can develop either in lymph nodes or in ‘extranodal sites’ (areas outside the lymph nodes). When DLBCL reappears or grows again after a period of remission, it is called as ‘relapsed’ while the term ‘refractory’ is used to define the situation when the lymphoma does not respond to treatment

The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Figure 1. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Share (%) in Terms of Value, By Region, 2020

Relapsed or Refractory Diffuse Large B-cell Lymphoma  | Coherent Market Insights

Significant prevalence of diffuse large B-cell lymphoma is expected to propel the market growth over the forecast period

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL). According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S.

Moreover, the Surveillance, Epidemiology, and End Results (SEER) Program, which provides information on cancer statistics among the U.S. population, estimated the percent of cases diagnosed according to the stages which is given in graph below

Figure 2. Diffuse Large B-cell Lymphoma Cases by Stages in the U.S.

Relapsed or Refractory Diffuse Large B-cell Lymphoma  | Coherent Market Insights

Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities is expected to drive the market growth over the forecast period

Market players are focusing on approvals for relapsed or refractory diffuse large B-cell lymphoma therapeutics from regulatory authorities which is expected to accelerate the market growth. On February 8, 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

request-sample

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2020: US$ 1,364 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2021 to 2028 CAGR: 4.2% 2028 Value Projection: US$ 1,975.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG 

Growth Drivers:
  • Increasing prevalence of diffuse large B-cell lymphoma 
  • Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities
Restraints & Challenges:
  • Side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma

Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 132 million cases and 2.87 million deaths due to coronavirus disease (COVID-19) were reported till April 7, 2021 across the globe.

Rapidly increasing cases of COVID-19 caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrollment, in order to minimize the risk of contracting COVID-19 and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Furthermore, travel restrictions, patient concerns of contracting coronavirus infection, and others are some of the factors responsible for the withdrawal of patients from the clinical trial.

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Restraint

However, side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma are expected to hinder the market growth. For example, common adverse reactions occurring in diffuse large B-cell lymphoma patients when treated with MONJUVI (tafasitamab-cxix) are listed below:

  • Infusion reaction such as headache, shortness of breath, and chills during the infusion of MONJUVI
  • Low blood cell counts of red blood cells, white blood cells, and platelets is common when patients are treated with MONJUVI which can become life threatening
  • The patients can acquire life threatening infections. Patients should inform their doctors if they get fever of 100.4°F (38°C) or above

Apart from the above stated adverse events, common side effects associated with MONJUVI administration includes diarrhea, cough, fever, decreased appetite, respiratory tract infection, swelling of lower legs or hands, and fatigue.

Key Players

Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.

Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)

Key features of the study:

  • This report provides in-depth analysis of the global relapsed or refractory diffuse large B-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global relapsed or refractory diffuse large B-cell lymphoma market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global relapsed or refractory diffuse large B-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B-cell Lymphoma market.

Detailed Segmentation:

  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type:
    • Monjuvi
    • XPOVIO
    • Polivy
    • Kymriah
    • Yescarta
    • Others
  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region:
    • North America
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Monjuvi
        • XPOVIO
        • Polivy
        • Kymriah
        • Yescarta
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • MorphoSys US Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Karyopharm Therapeutics
    • Hoffmann-La Roche AG
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Novartis AG

 “*” marked represents similar segmentation in other categories in the respective section.      

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Safety Syringes for COIVD-19 Vaccines
  5. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Monjuvi  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • XPOVIO
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Polivy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Kymriah
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Yescarta
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • MorphoSys US Inc.  
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol Myers Squibb
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Karyopharm Therapeutics
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 36 market data tables and 35 figures on "Relapsed or Refractory Diffuse Large B-cell Lymphoma Market” - Global forecast to 2028

Frequently Asked Questions

The global relapsed or refractory diffuse large B-cell lymphoma market size is estimated to surpass US$ 1,937.99 million by 2028.
The market is expected to register a CAGR of 4.2% during the forecast period (2021-2028).
Increasing prevalence of diffuse large B-cell lymphoma and increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities are driving the market growth.
XPOVIO segment is expected to hold the major market share, owing to increasing approvals by regulatory authorities.
North America relapsed or refractory diffuse large B-cell lymphoma market is expected to generate highest revenue share during the forecast period.
Major factors hampering growth of the market include side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner